WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The leadership of WuXi PharmaTech, China's top contract research organization, has spelled out for the first time in detail how its ill-timed acquisition of an American biologics manufacturing and testing outfit, lashed by the tempests of the West's financial crisis, triggered a massive loss that wiped out five years of earnings
You may also be interested in...
How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)
[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]
How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)
[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]
WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year